Physician profile
Robert E Caro
NPI 1316944903
$3,191.04
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $894 · 2021: $712 · 2022: $626 · 2024: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $716.42 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $462.81 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $298.18 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $295.09 | 2019-2024 | Airsupra |
| Amgen INC. | $227.40 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $184.55 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.78 | 2019-2021 | |
| Pfizer INC. | $97.88 | 2019-2024 | |
| Glaxosmithkline, LLC. | $90.87 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $87.14 | 2019-2021 | |
| Corcept Therapeutics | $79.99 | 2021-2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $66.55 | 2019-2021 | |
| Abbott Laboratories | $48.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.53 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.97 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $39.20 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $34.08 | 2022 | |
| Shire North American Group INC | $33.64 | 2019 | |
| Radius Health, INC. | $26.51 | 2019 | |
| Dexcom, INC. | $25.51 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $24.54 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.34 | 2024 | Voquezna |
| Genentech USA, INC. | $20.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.24 | 2021 | |
| Astellas Pharma US INC | $13.71 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.